[SCYX] SCYNEXIS, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.53 Change: 0.15 (4.44%)
Ext. hours: Change: 0 (0%)

chart SCYX

Refresh chart

Strongest Trends Summary For SCYX

SCYX is in the medium-term up 170% in 6 months. In the long-term down -85% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -28.97% Sales Growth - Q/Q-37.76% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-31.64% ROE-40.2% ROI
Current Ratio5.81 Quick Ratio Long Term Debt/Equity Debt Ratio0.19
Gross Margin16.46% Operating Margin-94.89% Net Profit Margin-62.61% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities100 K Cash From Investing Activities-170 K Cash From Operating Activities-4.55 M Gross Profit70 K
Net Profit-6.38 M Operating Profit-6.38 M Total Assets34.86 M Total Current Assets29.83 M
Total Current Liabilities5.13 M Total Debt Total Liabilities7.42 M Total Revenue3.3 M
Technical Data
High 52 week2.01 Low 52 week0.38 Last close1.65 Last change-0.6%
RSI34.04 Average true range0.11 Beta0.53 Volume224.9 K
Simple moving average 20 days-2.71% Simple moving average 50 days9.16% Simple moving average 200 days38.97%
Performance Data
Performance Week-2.94% Performance Month16.2% Performance Quart130.13% Performance Half57.14%
Performance Year34.15% Performance Year-to-date242.54% Volatility daily3.58% Volatility weekly8%
Volatility monthly16.4% Volatility yearly56.81% Relative Volume222.3% Average Volume1.45 M
New High New Low

News

2019-06-20 11:13:00 | Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019

2019-06-19 13:18:47 | Imagine Owning SCYNEXIS NASDAQ:SCYX And Trying To Stomach The 84% Share Price Drop

2019-06-14 08:30:00 | SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development

2019-06-07 09:27:00 | Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

2019-06-05 08:30:00 | SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections

2019-05-30 08:30:00 | SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp

2019-05-08 19:35:11 | Scynexis SCYX Reports Q1 Loss, Misses Revenue Estimates

2019-05-08 18:31:35 | Scynexis: 1Q Earnings Snapshot

2019-05-08 16:15:00 | SCYNEXIS Reports First Quarter 2019 Financial Results and Provides Company Update

2019-05-07 10:30:02 | Scynexis SCYX Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2019-05-06 08:30:00 | SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis VVC

2019-05-01 08:30:00 | SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis VVC

2019-04-15 08:30:00 | SCYNEXIS to Discuss ECCMID 2019 Clinical Data, Including Successful Case Studies in Candida auris and Other Difficult-to-Treat Infections, on Conference Call

2019-04-13 09:38:23 | The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

2019-04-12 10:08:00 | Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2019-04-08 08:15:00 | SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens

2019-04-03 08:30:00 | SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID

2019-04-01 08:00:00 | SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

2019-03-14 16:39:00 | SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update

2019-03-07 09:34:00 | SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note

2019-02-28 09:50:03 | Do Institutions Own Shares In SCYNEXIS, Inc. NASDAQ:SCYX?

2019-02-28 08:30:00 | SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019

2019-01-31 09:20:00 | 4 Biotech Stocks Making Moves On Thursday 1/31/19

2019-01-30 16:05:00 | SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies

2019-01-22 08:45:00 | SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors

2019-01-21 11:24:49 | Does SCYNEXIS, Inc.’s NASDAQ:SCYX CEO Salary Reflect Performance?

2019-01-17 10:00:00 | Antimicrobials Working Group Announces Updates to Leadership Team

2019-01-04 07:59:58 | The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO

2019-01-03 16:05:00 | SCYNEXIS Provides Year-end Update and Outlines Plans for 2019

2018-11-23 08:00:00 | Report: Developing Opportunities within ReWalk Robotics, ImmuCell, SCYNEXIS, Fuel Tech, Garrison Capital, and AMREP — Future Expectations, Projections Moving into 2018

2018-11-20 08:00:00 | SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

2018-11-13 10:25:03 | Scynexis SCYX Reports Q3 Loss, Tops Revenue Estimates

2018-11-13 09:19:31 | Scynexis: 3Q Earnings Snapshot

2018-11-13 09:05:00 | SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update

2018-10-23 09:00:00 | SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp

2018-10-15 09:26:00 | SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections CARES

2018-10-01 09:25:00 | SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week

2018-09-26 08:00:00 | SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018

2018-09-25 08:00:00 | SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

2018-09-18 08:29:11 | Who Owns SCYNEXIS Inc NASDAQ:SCYX?

2018-08-29 11:52:28 | 5 Healthcare Stocks That Are Down, But Not Out!

2018-08-29 08:00:00 | SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

2018-08-09 18:45:10 | Scynexis SCYX Reports Q2 Loss, Lags Revenue Estimates

2018-08-09 17:43:39 | Scynexis: 2Q Earnings Snapshot

2018-08-09 16:15:00 | SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update

2018-07-30 07:10:00 | Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks

2018-07-18 08:05:00 | The World Health Organization Recognizes New Antifungal Class by Granting _ibrexafungerp_ to SCYNEXIS as the International Non-Proprietary Name for SCY-078

2018-07-12 09:49:08 | Why Scynexis Stock Rose 16.4% Yesterday

2018-07-10 16:05:00 | SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

2018-07-02 07:25:00 | Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks